Vera Therapeutics ORIGIN 3 trial meets all endpoints for IgAN drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Vera Therapeutics ORIGIN 3 trial meets all endpoints for IgAN drug

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of M

October 22, 2026 10:05 AM EDT

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events.Favorable safety profile, and generally comparable to placebo. Plan to submit supplemental BLA to the U.S. FDA in Q4 2026 for full approval expected in 2027.Investor webcast is scheduled for October 22 at 4:30 pm EDT.

BRISBANE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE)... More